Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0GPLFP |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | 023 (CD123) |
|||||
| Organization | CSPC MEGALITH BIOPHARMACEUTICAL CO.,LTD. |
|||||
| Synonyms |
023 (CD123)
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Interleukin-3 receptor subunit alpha (IL3RA) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYNDGTKY
NEKFKGRATLTSDRSTSTAYMELSSLRSEDTAVYYCAREGGNDYYDTMDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLCLSPG Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
SSIMH
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
YIKPYNDGTKYNEKFKG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
EGGNDYYDTMDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYRVNRLVDGVPS
RFSGSGSGNDYTLTISSLQPEDFATYYCLQYDAFPYTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
RASQDINSYLS
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
RVNRLVD
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
LQYDAFPY
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
wO2024222841A1 ADC60 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
63%
|
High CD123 expression (CD123+++) | ||
| Method Description |
Investigated the antitumour effect of 5mg/kg ADC in a CD33highCD123high MV-4-11 xenograft NOD SCID mice tumour model, D19.
|
||||
| In Vivo Model | CD123-high MV-4-11 xenograft NOD SCID mice tumour model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.2666 pM
|
High CD33 expression (CD33+++) | ||
| Method Description |
Cytotoxicity of ADC to MV4-11 cells
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
wO2024222841A1 ADC67 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
12.3 pM
|
High CD33 expression (CD33+++) | ||
| Method Description |
Cytotoxicity of ADC to MV4-11 cells
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||